-
3 Biotechs That Have Doubled Investors' Money in Less Than a Year
biospace
January 24, 2018
Having a stock double in value is a good thing. Having it double—or more—in a year is even better. Keith Speights, writing for The Motley Fool, looks at three healthcare stocks that have doubled in less than 12 months.
-
What You Need to Know About Tango Therapeutics
biospace
January 17, 2018
Tango Therapeutics was officially launched in March 2017 as a cancer drug target discovery and drug development company.
-
Boehringer Ingelheim Ups Venture Fund to €250M
biospace
January 04, 2018
Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M€
-
Cambridge-Based Aura Biosciences Scoops Up $30M
biospace
December 26, 2017
Aura Biosciences, a?biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it closed a $30 million Series C financing.
-
NovaBay Pharmaceuticals Receives Stockholder Approval for Proposed $10.32 Million Financing Agreemen
biospace
December 25, 2017
NovaBay Pharmaceuticals (NYSE: NBY) Announces Shareholders' Approval of Issuance of NovaBay Common Shares as part of a $ 10.32M facility agreement with Gemstone Capital (Beijing) Co., Ltd.
-
Pionyr Immunotherapeutics gains meaty $62M series B
fiercebiotech
December 14, 2017
California startup Pionyr is using $62 million of VC-backed funding to target antibodies in the tumor microenvironment.
-
UK Government commits ￡210M to grow Life Science Sector
biospectrumasia
December 11, 2017
Government has committed up to ￡210 million ($280.9 million) to expand early diagnostics programs, genomics research, and artificial intelligence-driven science
-
GSK to invest ￡40m in UK's life sciences sector
pharmaceutical-business-review
December 08, 2017
GlaxoSmithKline (GSK) has agreed to invest ￡40m in genetic research as part of the UK Government’s life sciences sector deal.
-
Cambridge Biotech Obsidian Launches With $49.5M Investment From Google, Takeda, Vertex, Amgen, Ot
biospace
December 07, 2017
Obsidian Therapeutics?officially launched with the completion of a Series A financing worth $49.5 million.
-
The UK Government announces major life sciences venture as it unveils its industrial strategy
biospectrumasia
November 28, 2017
The UK’s business department has secured a major multi-million pound investment with a leading Life Sciences firm, MSD, known as Merck and co. in North America.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
